Comparative Pharmacology
Head-to-head clinical analysis: LIGNOSPAN FORTE versus MEPIVACAINE HYDROCHLORIDE W LEVONORDEFRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIGNOSPAN FORTE versus MEPIVACAINE HYDROCHLORIDE W LEVONORDEFRIN.
LIGNOSPAN FORTE vs MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.
Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 mL per site.
Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.
None Documented
None Documented
Terminal elimination half-life of lidocaine: 1.5–2 hours; in hepatic impairment or heart failure, may extend to >4 hours. For the vasoconstrictor (epinephrine), half-life is approximately 2 minutes due to rapid uptake and metabolism.
Terminal elimination half-life is approximately 2-3 hours in adults. In neonates, half-life is prolonged (8-10 hours due to immature hepatic function). Clinical context: Short half-life reduces risk of systemic accumulation with repeated doses.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and other conjugates): ~90%; biliary/fecal: <10% as unchanged drug.
Mepivacaine is primarily metabolized in the liver via N-demethylation and hydroxylation. Less than 5% is excreted unchanged in urine. Hepatic clearance accounts for >90% of elimination; renal excretion of metabolites accounts for the remainder. Fecal elimination is minimal (<2%).
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor